Literature DB >> 19381887

Exacerbation of thyroid associated ophthalmopathy after arterial embolization therapy in a patient with Graves' disease.

Tetsuya Hiraiwa1, Akihisa Imagawa, Kazuhiro Yamamoto, Hiroshi Arimoto, Takeshi Arishima, Mitsuru Ito, Yasushi Nakamura, Fumio Matsuzuka, Akira Miyauchi, Jun Sugasawa, Tsunehiko Ikeda, Yoshifumi Narumi, Toshiaki Hanafusa.   

Abstract

A novel treatment approach to Graves' disease (GD), embolization of the thyroid gland arteries, is evaluated with respect to its indications and adverse effects. We describe an exacerbation of thyroid associated ophthalmopathy (TAO) following thyroid artery embolization in a woman with GD and mild stable TAO (NOSPECS classification, class I grade a). A 45-year-old woman with GD and inactive TAO, in whom thyroid function was stable following blockade of hormone release combined with replacement therapy, underwent embolization of three thyroid arteries. Initially, there were neither adverse effects nor complications; however, the patient developed severe TAO (NOSPECS classification, class IV grade b) 3 months after the arterial embolization. Steroid pulse treatments followed by total thyroidectomy resulted in improvement of the eye signs and symptoms. The clinical course and the serial changes of the thyroglobulin and thyroglobulin-antibody titers suggested that the destruction of thyroid follicles, induced by the arterial embolization, triggered the exacerbation of her TAO. Our experience argues for the use of caution when arterial embolization is considered for GD patients with even the mildest TAO (NOSPECS classification, class I).

Entities:  

Mesh:

Year:  2009        PMID: 19381887     DOI: 10.1007/s12020-009-9177-z

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  10 in total

Review 1.  Graves' disease.

Authors:  A P Weetman
Journal:  N Engl J Med       Date:  2000-10-26       Impact factor: 91.245

2.  Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association.

Authors:  S C Werner
Journal:  J Clin Endocrinol Metab       Date:  1977-01       Impact factor: 5.958

3.  [First clinical experience of radio-endovascular functional thyroidectomy in the treatment of diffuse toxic goiter].

Authors:  E V Galkin; B S Grakov; A V Protopopov
Journal:  Vestn Rentgenol Radiol       Date:  1994 May-Jun

Review 4.  Management of Graves' ophthalmopathy: reality and perspectives.

Authors:  L Bartalena; A Pinchera; C Marcocci
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

5.  Total thyroidectomy for the treatment of hyperthyroidism in patients with ophthalmopathy.

Authors:  Hideo Kurihara
Journal:  Thyroid       Date:  2002-03       Impact factor: 6.568

6.  Thyroid arterial embolization to treat Graves' disease.

Authors:  W Zhao; B-L Gao; H-Y Yang; H Li; D-P Song; S-T Xiang; J Shen
Journal:  Acta Radiol       Date:  2007-03       Impact factor: 1.990

7.  Arterial embolization: a novel approach to thyroid ablative therapy for Graves' disease.

Authors:  Haipeng Xiao; Wenquan Zhuang; Shenming Wang; Binjie Yu; Guorui Chen; Muheng Zhou; Norman C W Wong
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

8.  Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment?

Authors:  L Tallstedt; G Lundell; H Blomgren; J Bring
Journal:  Eur J Endocrinol       Date:  1994-05       Impact factor: 6.664

9.  Retrospective evaluation of subtotal and total thyroidectomy in Graves' disease with and without endocrine ophthalmopathy.

Authors:  B Winsa; J Rastad; G Akerström; H Johansson; K Westermark; F A Karlsson
Journal:  Eur J Endocrinol       Date:  1995-04       Impact factor: 6.664

10.  Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of graves' ophthalmopathy.

Authors:  Mariacarla Moleti; Filiberto Mattina; Ignazio Salamone; Maria Antonia Violi; Carmelo Nucera; Sergio Baldari; Maria Grazia Lo Schiavo; Concetto Regalbuto; Francesco Trimarchi; Francesco Vermiglio
Journal:  Thyroid       Date:  2003-07       Impact factor: 6.568

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.